Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Current Value
$38.581 Year Return
Current Value
$38.581 Year Return
Market Cap
$2.82B
P/E Ratio
-10.18
1Y Stock Return
79.34%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
5.3
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYCN | -0.04% | $4.77M | -16.19% | 0.00% |
NAT | 0.07% | $636.83M | -30.05% | 13.79% |
UNH | -0.10% | $531.00B | +6.93% | 1.37% |
SGC | -0.10% | $261.95M | +41.61% | 4.32% |
HUM | -0.11% | $33.45B | -45.22% | 1.25% |
MMC | -0.12% | $108.41B | +10.89% | 1.37% |
YUM | 0.16% | $36.88B | +3.04% | 1.98% |
CMTL | -0.21% | $84.44M | -76.16% | 0.00% |
MNR | 0.22% | $1.66B | -10.71% | 15.90% |
CORZ | -0.22% | $4.60B | +3,201.26% | 0.00% |
SNCR | 0.27% | $97.34M | +78.17% | 0.00% |
CECO | -0.28% | $1.04B | +48.90% | 0.00% |
CIG.C | -0.30% | $2.48B | -3.55% | 0.00% |
FAST | 0.32% | $46.74B | +35.26% | 1.92% |
ZH | 0.33% | $333.09M | -40.59% | 0.00% |
CREG | 0.38% | $6.14M | -35.78% | 0.00% |
CNA | 0.40% | $13.16B | +23.03% | 3.61% |
AGX | -0.40% | $2.01B | +224.91% | 0.85% |
AXS | -0.40% | $7.14B | +55.12% | 2.06% |
SCWX | 0.42% | $743.12M | +40.27% | 0.00% |
Yahoo
Shareholders of SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) will be pleased this week, given that the stock price is...
Yahoo
SpringWorks Therapeutics Inc (SWTX) reports a 23% revenue increase and anticipates FDA approval for a new treatment, despite short-term challenges.
Yahoo
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section o
SeekingAlpha
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call November 12, 2024 8:30 AM ETCompany ParticipantsKim Diamond - Vice President, Corporate...
Yahoo
SpringWorks Therapeutics (SWTX) announced that data from the pivotal, Phase 2b ReNeu trial of mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas, or NF1-PN, were published online in the Journal of Clinical Oncology. As of September 20, 2023, the ReNeu trial met its primary endpoint of confirmed objective response rate. During the 24-cycle treatment phase, the ORR was 41% in adults and 52% in children re
Yahoo
– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children w
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OXBR | -16.73% | $19.05M | +178.18% | 0.00% |
CBOE | -13.50% | $21.46B | +15.84% | 1.11% |
CAH | -13.34% | $28.64B | +12.14% | 1.70% |
MNOV | -11.28% | $93.19M | +2.15% | 0.00% |
MCK | -9.42% | $78.15B | +35.51% | 0.42% |
MAGN | -9.37% | $638.97M | -3.42% | 0.00% |
COR | -9.34% | $47.48B | +21.20% | 0.86% |
KDP | -9.29% | $42.76B | -1.22% | 2.77% |
CME | -9.13% | $82.76B | +9.21% | 1.98% |
KNOP | -9.13% | $210.40M | +11.75% | 1.68% |
COCO | -8.46% | $2.01B | +24.49% | 0.00% |
NHTC | -8.42% | $61.83M | +0.19% | 14.81% |
LITB | -8.41% | $35.48M | -75.45% | 0.00% |
LUMO | -8.01% | $37.45M | +41.97% | 0.00% |
TTEK | -7.44% | $10.90B | +23.97% | 2.70% |
FRO | -7.37% | $4.56B | -7.37% | 9.36% |
ACGL | -6.73% | $36.00B | +16.84% | 0.00% |
DMLP | -6.51% | $1.58B | +18.00% | 10.54% |
HUSA | -6.50% | $16.69M | -11.56% | 0.00% |
AQB | -6.41% | $3.78M | -37.77% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RNA | 38.91% | $5.16B | +638.05% | 0.00% |
BCRX | 37.85% | $1.49B | +41.37% | 0.00% |
FARO | 37.53% | $486.17M | +40.51% | 0.00% |
RVMD | 35.21% | $9.50B | +171.62% | 0.00% |
DAWN | 34.81% | $1.36B | +13.42% | 0.00% |
ARQT | 34.42% | $1.18B | +433.86% | 0.00% |
EVGO | 34.23% | $625.86M | +97.63% | 0.00% |
CARM | 33.79% | $36.20M | -64.46% | 0.00% |
MFA | 33.78% | $1.13B | +5.15% | 12.73% |
NNOX | 33.76% | $332.87M | -7.63% | 0.00% |
SAGE | 33.46% | $300.36M | -74.61% | 0.00% |
IDYA | 33.27% | $2.24B | -15.21% | 0.00% |
PGRE | 33.19% | $1.04B | +5.31% | 2.23% |
AAT | 33.08% | $1.70B | +49.52% | 4.83% |
DX | 32.91% | $991.29M | +9.75% | 12.54% |
NTLA | 32.91% | $1.44B | -50.35% | 0.00% |
BRSP | 32.76% | $806.64M | -3.86% | 12.20% |
CMPS | 32.73% | $325.68M | -18.35% | 0.00% |
AXSM | 32.64% | $4.63B | +61.30% | 0.00% |
LAW | 32.42% | $325.90M | -3.37% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -29.57% | $388.04M | 1.43% |
VIXY | -20.77% | $195.31M | 0.85% |
TPMN | -15.45% | $40.60M | 0.65% |
TAIL | -13.22% | $67.98M | 0.59% |
CORN | -11.36% | $61.12M | 0.2% |
USDU | -10.39% | $201.97M | 0.5% |
CTA | -9.77% | $350.27M | 0.78% |
JUCY | -9.15% | $324.29M | 0.6% |
JBBB | -8.87% | $1.26B | 0.49% |
KMLM | -7.44% | $353.87M | 0.9% |
UNG | -7.20% | $908.80M | 1.06% |
SOYB | -6.89% | $27.32M | 0.22% |
KRBN | -6.43% | $242.47M | 0.85% |
WEAT | -6.20% | $120.27M | 0.28% |
EQLS | -5.81% | $76.08M | 1% |
MINT | -5.53% | $11.62B | 0.35% |
AGZD | -5.30% | $142.76M | 0.23% |
ICLO | -5.21% | $209.30M | 0.2% |
DBE | -5.05% | $50.13M | 0.77% |
UUP | -5.00% | $309.25M | 0.77% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BOXX | 0.13% | $4.43B | 0.1949% |
CGSM | -0.15% | $514.53M | 0.25% |
TBIL | -0.18% | $4.38B | 0.15% |
XBIL | 0.28% | $637.70M | 0.15% |
HIGH | 0.39% | $302.78M | 0.51% |
DFSD | 0.40% | $3.63B | 0.16% |
SHV | 0.82% | $18.13B | 0.15% |
HDRO | -0.93% | $164.26M | 0.3% |
KCCA | -1.66% | $220.51M | 0.87% |
GBIL | 1.69% | $5.60B | 0.12% |
FLRN | -1.86% | $2.33B | 0.15% |
XONE | 2.08% | $548.88M | 0.03% |
DBA | -2.08% | $755.88M | 0.93% |
CLOI | -2.29% | $715.40M | 0.4% |
DBO | 2.36% | $217.57M | 0.77% |
FLTR | 2.50% | $1.79B | 0.14% |
BUXX | 2.53% | $162.67M | 0.25% |
BILZ | 2.58% | $563.02M | 0.14% |
CSHI | 2.69% | $482.85M | 0.38% |
UCON | 2.85% | $3.19B | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 45.97% | $6.58B | 0.35% |
PTH | 41.45% | $143.31M | 0.6% |
FHLC | 38.80% | $2.73B | 0.084% |
IBB | 38.37% | $6.66B | 0.45% |
PINK | 38.10% | $161.15M | 0.5% |
VHT | 38.05% | $17.06B | 0.1% |
PBE | 37.92% | $258.53M | 0.58% |
XPH | 37.09% | $157.87M | 0.35% |
RIET | 36.98% | $88.96M | 0.5% |
EDOC | 36.81% | $40.86M | 0.68% |
IWC | 36.64% | $933.99M | 0.6% |
IWO | 36.62% | $12.56B | 0.24% |
IBUY | 36.39% | $176.17M | 0.65% |
FXH | 36.33% | $1.15B | 0.62% |
GSSC | 36.15% | $529.86M | 0.2% |
QCLN | 36.08% | $574.08M | 0.59% |
FYX | 36.06% | $959.00M | 0.6% |
MORT | 35.89% | $293.96M | 0.43% |
REM | 35.87% | $632.41M | 0.48% |
XHE | 35.85% | $213.41M | 0.35% |